Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 2252-2260

  Yong, Hyun Jeon ^a   Choi, Yun ^a   Sun, Och Yoon ^a   Chul, Woo Kim ^a   Chung, June Key ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; IODINE 131; PERTECHNETIC ACID TC 99M; PROLYLASPARTYLTHREONYLARGINYLPROLYLALANYLPROLYLGLYCYLSERYL THREONYLALANYLPROLYLPROLYLALANYLHISTIDYLGLYCYLVALYLTHREONYLSERYLALANYL PROLYLASPARTYLTHREONYLARGINYLPROLYLALANYLPROLYLGLYCYLSERYLTHREONINE; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG; CA 15-3 ANTIGEN; COTRANSPORTER; GLYCOPROTEIN P 15095; MUC1 PROTEIN, HUMAN; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL COUNT; CELL PROLIFERATION; DRUG SCREENING; GENETICS; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; TUMOR CELL LINE; VACCINATION;

ANIMALS; ANTIGENS, CD11C; CA-15-3 ANTIGEN; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; INTERFERON TYPE II; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; NEOPLASMS; SYMPORTERS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR STEM CELL ASSAY; VACCINATION; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51049087087     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0277     Document Type: Article

References (41)

1. Watters D. Molecular mechanisms of ionizing radiation-induced apoptosis. Immunol Cell Biol 1999;77:263-71.
2. Chakravarty PK, Alfieri A, Thomas EK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999;59:6028-32.
3. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.
4. Nikitina EY, Gabrilovich DI. Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 2001;94:825-33.
5. Klein B, Loven D, Lurie H, et al. The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture. J Neurosurg 1994;80:1074-7.
6. Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer 1997;73:757-62.
7. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
8. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655-66.
9. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
10. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988;263:12820-3.
11. Mushenkova N, Moiseeva E, Chaadaeva A, Den Otter W, Svirshchevskaya E. Antitumor effect of double immunization of mice with mucin 1 and its coding DNA. Anticancer Res 2005;25:3893-8.
12. Snyder LA, Goletz TJ, Gunn GR, et al. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 2006;24:3340-52.
13. Kontani K, Taguchi O, Ozaki Y, et al. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther 2002;9:330-7.
14. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucleic Med 2002;43:1188-200.
15. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000;80:1083-105.
16. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000;60:6526-30.
17. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001;8:1524-31.
18. Chen L, Altmann A, Mier W, et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucleic Med 2006;47:854-62.
19. Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005;12:272-80.
20. Jeon YH, Choi Y, Kim HJ, et al. Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine. Int J Cancer 2007;121:1593-9.
21. Mandell RB, Mandell LZ, Link CJ, Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59:661-8.
22. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997;185:909-20.
23. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998;392:408-11.
24. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998;4:1281-6.
25. Livingston PO, Kaelin K, Pinsky CM, Oettgen HF, Old LJ. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Cancer 1985;56:2194-200.
26. Berd D, Maguire HC, Jr., McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67.
27. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
28. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-22.
29. + T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998;72:5648-53.
30. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
31. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-74.
32. Kim TW, Hung CF, Ling M, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003;112:109-17.
33. Kim TW, Hung CF, Juang J, He L, Hardwick JM, Wu TC. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther 2004;11:336-42.
34. Rosenberg SA, Yang JC, Sherry RM, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003;14:709-14.
35. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-80.
36. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: the sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001;86:3327-35.
37. Vallabhajosula S. Radiopharmaceuticals in oncology. In: Khalkhali IMJ, Goldsmith SJ, editors. Nuclear oncology: diagnosis and therapy. Philadelphia (PA): Lippincott,Williams & Wilkins; 2001. p. 31-62.
38. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94.
39. Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001;22:141-8.
40. Kang JH, Chung JK, Lee YJ, et al. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucleic Med 2004;45:1571-6.
41. Lee YJ, Chung JK, Shin JH, et al. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 2004;14:889-95.